- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| Mi | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| Mi | GENFLEET-B (02595): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| Mi | GENFLEET-B (02595): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) CHANGE OF THE JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| Fr | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRECLINICAL RESEARCH DATA OF THREE LARGE- AND SMALL-MOLECULE TARGETED THERAPIES RELEVANT TO RAS PATHWAY TO ... | 1 | HKEx | ||
| 11.03. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 09.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION INTO THE STOCK LIST OF THE STOCK CONNECT PROGRAM (SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG ... | 1 | HKEx | ||
| 02.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH FIRST BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR A KRAS G12D INHIBITOR TREATING NON-SMALL ... | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.02. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG INDEX SERIES AND MSCI INDEX | - | HKEx | ||
| 09.02. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 09.02. | GENFLEET-B (02595): (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 9, 2026; AND (2) ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND ... | - | HKEx | ||
| 23.01. | GENFLEET-B (02595): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, FEBRUARY 9, 2026 | 4 | HKEx | ||
| 23.01. | GENFLEET-B (02595): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 23.01. | GENFLEET-B (02595): (1) PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME (2) PROPOSED ADOPTION OF THE H SHARE INCENTIVE SCHEME (3) PROPOSED AUTHORISATION ... | 2 | HKEx | ||
| 20.01. | GENFLEET-B (02595): PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 05.12.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST SITE INITIATED IN A REGISTRATIONAL STUDY OF GFH375 FOR METASTATIC PANCREATIC CANCER, AS FIRST-IN-WORLD ... | 1 | HKEx | ||
| 24.11.25 | GENFLEET-B (02595): PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME | 1 | HKEx | ||
| 22.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN A PHASE IB/II STUDY OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, COMBINED WITH CETUXIMAB ... | 2 | HKEx | ||
| 21.10.25 | Verastem stock falls after GenFleet's PDAC study shows lower efficacy data | 1 | Investing.com | ||
| 21.10.25 | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 9,605 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 27,560 | 0,00 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| MAZE THERAPEUTICS | 31,800 | 0,00 % | Maze Therapeutics: BTIG bestätigt Kaufempfehlung nach positiven Studiendaten | ||
| APOGEE THERAPEUTICS | 78,55 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 35,550 | 0,00 % | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts 'Upbeat' | ||
| BEAM THERAPEUTICS | 23,110 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ARCELLX | 114,53 | 0,00 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| SUMMIT THERAPEUTICS | 17,950 | 0,00 % | Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates | ||
| ERASCA | 15,990 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| TYRA BIOSCIENCES | 36,740 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| BICARA THERAPEUTICS | 18,680 | 0,00 % | BofA-Studie treibt Aktie von Bicara Therapeutics an | ||
| 4D MOLECULAR THERAPEUTICS | 9,880 | 0,00 % | RBC Capital raises 4D Molecular stock price target on pipeline progress | ||
| COGENT BIOSCIENCES | 36,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| NUVALENT | 97,98 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,175 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report |
Das Unternehmen GENFLEET THERAPEUTICS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.